DMSATechnescan1 mg kit for radiopharmaceutical preparation
Succimer
Read this leaflet carefully before you start using this medicine, as it contains important information for you.
|
1. What isDMSATechnescanand what is it used for
2. What you need to know before usingDMSATechnescan
3. How to useDMSATechnescan
4. Possible side effects
5. Storage ofDMSATechnescan
6. Contents of the pack and additional information
This medication is a radiopharmaceutical for diagnostic use only.
DMSA Technescan contains the active ingredient succimer. It is used for the preparation of an injectable radioactive solution of technetium (99mTc) succimer.
DMSA Technescan is used in adults and children to examine the kidneys. When injected, this medication temporarily accumulates in the kidneys. Due to its radioactivity, it can be detected outside the body using a special camera and images, known as scans, can be taken. These scans provide valuable information about thestructure and/or function of your kidneys.The administration of DMSA Technescan involves receiving a small amount of radioactivity. Your doctor and the nuclear medicine physician have considered that the clinical benefit you will obtain from the procedure with the radiopharmaceutical outweighs the risk due to radiation.
No use DMSA Technescan:
Warnings and precautions
Be especially careful with DMSA Technescan:
Consult your nuclear medicine doctor if any of the above applies to you. It may not be suitable for you. Your nuclear medicine doctor will advise you.
Before administering DMSA Technescan, you must
Children and adolescents
Inform your nuclear medicine doctor if you are under 18 years old.
Other medications and DMSA Technescan
Inform your nuclear medicine doctor if you are using, have used recently, or may need to use any other medication, including over-the-counter medications, as they may interfere with image interpretation.
Your nuclear medicine doctor/doctor may recommend that you stop taking the following medications before the DMSA Technescan procedure:
Some cancer medications (methotrexate, cyclophosphamide, vincristine) may also influence or be influenced by DMSA Technescan.
Pregnancy and lactation
If you are pregnant or breastfeeding, or think you may be, consult your nuclear medicine doctor before using this medication.
You must inform your nuclear medicine doctorbeforeadministering DMSA Technescan if there is any possibility of pregnancy, if you have a delayed period, or if you are breastfeeding.
In case of doubt, it is essential to consult your nuclear medicine doctor who supervises the procedure.
If you are pregnant
Your nuclear medicine doctorwill onlyadminister DMSA Technescan during pregnancy if the expected benefit outweighs the risk.
If you are breastfeeding
Consult your nuclear medicine doctor if you are breastfeeding as they maydelaythe treatment until breastfeeding has ended. They may also ask you tointerruptbreastfeeding for a short period and discard this milk during that period until the radioactivity is no longer in your body. Please consult your nuclear medicine doctor when you can resume breastfeeding.
You do not need to avoid close contact with your baby after the procedure.
Driving and using machines
It is considered unlikely that DMSA Technescan will affect your ability to drive or use machines.
DMSATechnescan contains sodium
This medication contains less than 1 mmol (23 mg) of sodium per dose; it is “sodium-free”.
The nuclear medicine physician overseeing the procedure will decide on the amount of technetium (99mTc) succimer that should be used in your case. This will be the minimum amount necessary to obtain the desired information.
The generally recommended dose for an adult is30 to 120 MBq(MegaBecquerel, the unit used to express radioactivity).
Use in Children and Adolescents
In children and adolescents, the dose to be administered will be adjusted according to their body weight.
Administration of DMSA Technescan and Procedure Performance
DMSA Technescan is administered by injection, usually in a vein of the arm.
One injection is sufficient to perform the procedure your doctor needs.
After the injection, you will be offered a drink and asked to urinate immediately before starting the procedure.
Procedure Duration
The examinations are usually performed 2 to 3 hours after the injection. In some cases, they may be delayed up to 24 hours after the injection. Your nuclear medicine doctor will inform you about the duration of the procedure.
After DMSA Technescan Administration, You Must:
Your nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medication. Consult with your nuclear medicine doctor if you have any doubts.
If You Have Been Administered More DMSA Technescan Than Necessary
It is unlikely to have an overdose because you will receive a controlled and precise dose of DMSA Technescan from the nuclear medicine doctor overseeing the procedure. However, in the event of an overdose, you will receive the appropriate treatment. In particular, the nuclear medicine doctor may recommend that you drink plenty of water and urinate frequently to eliminate radioactive residues from your body.
If you have any other questions about the use of DMSA Technescan, ask your nuclear medicine doctor who is overseeing the procedure.
Adverse effects of unknown frequency (cannot be estimated from available data):
The hospital staff will treat these reactions if they occur.
This radiopharmaceutical provides low levels of ionizing radiation associated with a very low risk of cancer and hereditary anomalies.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
This medication does not need to be stored by the patient. This medication will be stored under the responsibility of the specialist in appropriate facilities. Storage of radiopharmaceuticals will be carried out in accordance with national regulations on radioactive materials.
The following information is only for the specialist.
Do not use DMSA Technescan after the expiration date that appears on the label after CAD.
Composition of DMSA Technescan
One vial contains 1.2 milligrams of succimer
Appearance of the product and contents of the packaging
DMSA Technescan is a kit of reagents for radiopharmaceutical preparation intended to be used only by healthcare professionals. Before using it, the powder from the vial is mixed with a radioactive solution called technetium (99mTc) to form a technetium (99mTc) succimer solution.
DMSA Technescan is packaged in a colorless type I glass vial of 10 ml closed with a bromobutyl rubber stopper and sealed with an aluminum capsule.
One package contains 5 vials.
Holder of the marketing authorization and responsible for manufacturing:
Holder of the marketing authorization:
Curium Pharma Spain S.A.
Avenida Doctor Severo Ochoa, N.º 29
28100, Alcobendas, Madrid
Responsible for manufacturing:
Curium Netherlands B.V.
Westerduinweg 3.
1755 LE Petten
Netherlands
Last review date of this leaflet: November 2023
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
This information is intended solely for healthcare professionals:
The complete technical file of DMSA Technescan is included as a separate document in the product packaging, in order to facilitate healthcare professionals with other scientific and practical information on the administration and use of this radiopharmaceutical. Please consult the technical file of DMSA Technescan.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.